13246-19-0

Basic information

• Product Name: Acetic acid, (2-acetyl-5-methoxyphenoxy)-, ethyl ester
• CAS NO: 13246-19-0
• Molecular Formula: C13H16O5
• Molecular Weight: 252.267
• Mol File: 13246-19-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Acetic acid, (2-acetyl-5-methoxyphenoxy)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, (2-acetyl-5-methoxyphenoxy)-, ethyl ester(13246-19-0)
• EPA Substance Registry System: Acetic acid, (2-acetyl-5-methoxyphenoxy)-, ethyl ester(13246-19-0)

Safety Data

• Hazardous Substances Data: 13246-19-0(Hazardous Substances Data)

Upstream product

• 105-36-2 ethyl bromoacetate 
• 552-41-0 1-(2-hydroxy-4-methoxyphenyl)ethanone 
• 105-39-5 chloroacetic acid ethyl ester 

Downstream Products

• 29048-57-5 paeonolacetic acid 
• 29040-52-6 6-methoxy-3-methylbenzofuran 
• 10410-29-4 6-methoxy-3-methyl-benzofuran-2-carboxylic acid 
• 53724-96-2 ethyl 6-methoxy-3-methylbenzofuran-2-carboxylate 
• 77956-75-3 8-Methoxy-benzo[b]oxepine-3,5-dione 
• 131453-00-4 (2S,3S)-3-Hydroxy-6-methoxy-3-methyl-2,3-dihydro-benzofuran-2-carboxylic acid ethyl ester 
• 131453-00-4 (2R,3S)-3-Hydroxy-6-methoxy-3-methyl-2,3-dihydro-benzofuran-2-carboxylic acid ethyl ester 
• 3710-50-7 ethyl 5-methoxy-3-methyl-1-benzofuran-2-carboxylate 

Relevant articles and documents

Novel paeonol derivatives: Design, synthesis and anti-inflammatory activity in vitro and in vivo

Paeonol has been proved to have potential anti-inflammatory activity, but its clinical application is not extensive due to the poor anti-inflammatory activity (14.74% inhibitory activity at 20 μM). In order to discover novel lead compound with high anti-inflammatory activity, series of paeonol derivatives were designed and synthesized, their anti-inflammatory activities were screened in vitro and in vivo. Structure-activity relationships (SARs) have been fully concluded, and finally (E)-N-(4-(2-acetyl-5-methoxyphenoxy)phenyl)-3-(3,4,5-trimet-hoxyphenyl)acrylamide (compound 11a) was found to be the best active compound with low toxicity, which showed 96.32% inhibitory activity at 20 μM and IC50 value of 6.96 μM against LPS-induced over expression of nitric oxide (NO) in RAW 264.7 macrophages. Preliminary mechanism studies indicated that it could inhibit the expression of TLR4, resulting in inhibiting of NF-κB and MAPK pathways. Further studies have shown that compound 11a has obvious therapeutic effect against the adjuvant-induced rat arthritis model.